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Reactive oxygen species (ROS) are products of normal cellular metabolism and derive from various sources in
different cellular compartments. Oxidative stress resultant from imbalance between ROS generation and antioxidant
defense mechanisms is important in pathogenesis of cardiovascular diseases, such as hypertension, heart failure,
atherosclerosis, diabetes, and cardiac hypertrophy. In this review we focus on hypertension and address sources of
cellular ROS generation, mechanisms involved in regulation of radical homeostasis, superoxide dismutase isoforms
in pathophysiology of hypertension; as well as radical intracellular signaling and phosphorylation processes in proteins
of the affected cardiovascular tissues. Finally, we discuss the transcriptional factors involved in redox-sensitive gene
transcription and antioxidant response, as well as their roles in hypertension.
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Introduction
Living organisms can reduce oxygen to water via aerobic
oxidative phosphorylation. This significantly shapes cel-
lular metabolism and energy production. The associated
oxygen intake results in the formation of toxic reactive
oxygen species (ROS) in the mitochondrial respiratory
chain. These radicals are electron donors and can dam-
age DNA, RNA, proteins, and lipids. They can also
propagate deleterious reactions throughout cells and tis-
sues resulting in cell death and apoptosis [1]. In addition,
ROS can alter gene expression by modulating the activa-
tion of transcription factors, with subsequent influence
on downstream target proteins that regulate cellular
functions such as cell growth and differentiation, modu-
late production and degradation of extracellular matrix,
inactivate nitric oxide (NO) functions, and stimulate
multiple kinases and proinflammatory gene expressions.
The ROS play an important role in the development
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Increased production of oxidants, reduced NO bioavail-
ability and reduced capacity of antioxidants in the vascular
system and kidneys are involved in these diseases [2].
Studies of the role of ROS and reactive nitrogen spe-
cies (RNS) in signal transduction have grown in number
during the past decade. The main interest in the field is
to recognize the specific targets and chemical reactions
involved in the signaling pathways triggered by ROS and
RNS as second messenger molecules. It was observed
that cysteine residues in the thiolate (ionized) form are
present in several classes of signaling proteins, and these
can be the specific targets for reactions with hydrogen
peroxide (H2O2) and RNS. These findings suggest that
in many signaling events where ROS and RNS take part,
enzymatic catalysis is more likely to be involved than a
non-enzymatic reaction [3]. As such, aberrant redox-
sensitive signal transduction is involved in pathophysi-
ology of hypertension [4-7]. In this review, it is not our
intention to provide a detailed survey on literature of
ROS in pathogenesis of hypertension, since many com-
prehensive reviews in this aspect are available [8-12].
We shall focus on different sources of ROS in the car-
diovascular systems and summarize current knowledge
on the redox-sensitive signaling in pathophysiology of
hypertension.tral Ltd. This is an open access article distributed under the terms of the Creative
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iginal work is properly cited.
Majzunova et al. Journal of Biomedical Science 2013, 20:69 Page 2 of 10
http://www.jbiomedsci.com/content/20/1/69ROS generation
Several mechanisms or pathways are responsible for the
production of free radicals in the cell [13,14]. A para-
digm has arisen over the past several years whereby
small amounts of radicals (so called “kindling radicals”)
can lead to formation of peroxynitrite, which oxidizes
tetrahydrobiopterin (BH4), leading to uncoupling of the
endothelial NO synthase (eNOS) and to formation of
large amounts of “bonfire” radicals [15]. As a result, pro-
duction of one free radical can lead to formation of other
radicals through a sequential chain reaction. According to
this “kindling-bonfire” theory of vascular oxidative stress,
there are primary, secondary and tertiary sources of ROS.
In general, nicotinamide adenine dinucleotide phosphate
(NADPH) oxidase acts as the primary source of super-
oxide anions (O2
-•) and H2O2 in the vessel wall. NADPH
oxidase-derived ROS then act as “kindling” and activate
secondary (uncoupled eNOS, xanthine oxidase), and ter-
tiary (mitochondrial) sources of ROS, which contribute to
the “bonfire” of radicals and oxidative stress seen at later
stages of diseases [16] (Figure 1).
NADPH oxidase-derived ROS and hypertension
ROS are derived from many sources in different cellular
compartments. In the vascular smooth muscle cells and
endothelial cells, NADPH oxidase acts as the primaryFigure 1 ROS sources and their function according to “kindlig-bonfiresource and is particularly important in pathophysiology of
hypertension (Figure 1). In the vascular system, ROS produc-
tion via the NADPH oxidase is triggered by stimulation of
neurohumoral vasoconstrictor agents, such as angiotensin II
(Ang II), endothelin-1 (ET-1) and norepinephrine (NE). The
action of Ang II through angiotensin type 1 (AT1) receptors
plays an important role in vasoconstriction. Activation of
AT1 receptors results in induction of a number of ROS-
producing events in the cell. Infusion of Ang II to normoten-
sive rats stimulates the production of O2
-• by NADPH
oxidase in vessels and induces pressor responses [17].
NADPH oxidase can also be activated by aldosterone and
ET-1 [18]. ET-1, the main endothelin form in the endothe-
lium, is a potent vasoconstrictor produced in various vas-
cular tissues including the endothelium. When delivered
in high concentrations, ET-1 acts as a vasoconstrictor and
is able to alter arterial pressure. The effects of ET-1 are
mediated by two isoforms of receptors, ETA and ETB. Ac-
tivation of ETA receptors causes contraction of blood
vessels via activation of the NADPH oxidase and gener-
ation of ROS; activation of ETB receptors leads to relax-
ation of vessels [19]. In cardiomyocytes, the production
of ROS is stimulated also by NE via α1-adrenergic recep-
tors (α1-AR). α1-AR, AT1, and ET-1 receptors are known
to activate NADPH oxidase through the G-protein,
resulting in the production of ROS [20]. Significance of” theory.
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hypertension was comprehensively discussed in several
recent reviews [12,21-23].
NOS uncoupling and hypertension
Under physiological conditions, NOS, in the presence of
substrate L-arginine and co-factor BH4, produces NO.
When BH4 levels are reduced, stability of NOS dimer
formation is altered such that the oxidase domain yields
molecular uncoupling and the catalytic activity becomes
functionally ‘uncoupled’ [12]. Enzymatic reduction of mo-
lecular oxygen by eNOS no longer couples to L-arginine,
resulting in the generation of deleterious O2
-• rather than
protective NO [24]. This eNOS uncoupling (Figure 1)
contributes to the increased ROS production and endo-
thelial dysfunction observed in various vascular diseases
[25,26], including hypertension [27]. Detailed discussion
on significance of eNOS uncoupling in pathogenesis of
hypertension is beyond the scope of this review and
readers are recommended to read other reviews [26-28] for
detailed discussion.
Mitochondrial ROS and hypertension
Mitochondrial electron transport chain is another im-
portant source of ROS generation. Any damage at en-
zyme complexes of the mitochondrial respiratory chain
leads to dysfunction of the mitochondrial respiration with
subsequent transfer of electrons to molecular oxygen in-
creasing the mitochondrial O2
-• and H2O2 formation [29].
In addition, increased mitochondrial peroxynitrite forma-
tion leads to nitration and inactivation of mitochondrial
antioxidant, manganese superoxide dismutase (MnSOD)
[30], which results in the impaired breakdown of mito-
chondrial O2
-• and further exacerbating in ROS production.
Finally, cytosolic ROS, via opening of the redox-dependent
mitochondrial ATP-sensitive potassium channels [31] and
changes in the mitochondrial membrane potential [32],
stimulates the mitochondrial ROS formation (Figure 1).
Reduced capacity of the mitochondrial respiratory chain
was observed in the brain stem of the spontaneously
hypertensive rats (SHR) and in neurogenic hypertension
induced by Ang II [33].
Mitochondria are integral component in energy me-
tabolism, ROS generation, and cell signaling, thus play
an important role in oxidative stress leading to the de-
velopment of many cardiovascular conditions, including
hypertension. The functional significance of mitochondria-
derived ROS, particularly in vascular cells, has recently
received a great attention. For example, hyperinsulinemia
induces migration and proliferation of vascular smooth
muscle cells via the increase in mitochondrial ROS [34].
Interestingly, production of free radicals and impairment
of mitochondrial function in young SHR has been affected
after long-term treatment with AT1R blocker, losartan.Glutamate-supported respiration, the rate of ATP produc-
tion, and concentrations of coenzyme Q9 (CoQ9), coen-
zyme Q10 (CoQ10), and alpha-tocopherol have all been
reported to improve mitochondrial dysfunctions and pro-
mote antihypertension in SHR after the therapy [35].
During acute hypoxia, O2
-• released from mitochondrial
Complex III of smooth muscle cells diffuses into the
cytosol and triggers increases in intracellular calcium and
causes acute hypoxic pulmonary vasoconstriction [36,37].
Moreover, mitochondrial ROS cross-talk with NADPH
oxidase markedly augments redox responses to Ang II in
the vascular smooth muscle cells [38]. This cross-talk be-
tween mitochondrial ROS and the NADPH oxidase in the
rostral ventrolateral medulla (RVLM), key nucleus for the
generation of sympathetic outflow from the brain stem,
was recently demonstrated to play an active role in mani-
festation of high arterial pressure in SHR [39].
Redox-sensitive intracellular signaling in hypertension
The term “redox signaling” describes a process in which
physiological levels of ROS induce modifications to pro-
teins that are discrete, site-specific, and reversible [40].
Evidence emerged over the past 2 decades suggests that
ROS modulate the activity of a vast array of intracellular
proteins and signaling pathways, and this redox signaling
is spatially and temporally regulated to generate specific
cellular effects under health and disease.
Until recently, ROS were considered only as harmful
molecules. However, recent studies suggest that ROS may
serve as an important physiological regulator of intracellu-
lar phosphorylation signaling pathways. The specific effects
of ROS are largely modulated by covalent modification of
specific cysteine residues, which were discovered in redox-
sensitive proteins. Oxidation of these reactive cysteine resi-
dues can lead to reversible modification of enzyme activity.
There is evidence that the ROS regulate various physio-
logical parameters in response to stimulation with growth
factors to generate inflammatory response. Disruption
of normal ROS signaling may lead to several diseases in
humans, including hypertension [41]. In hypertension,
neurohumoral stimuli such as Ang II, NE, and ET-1 acti-
vate receptors located on cell membrane, namely AT1,
α-AR, and ET receptors. The function of these receptors
is coupled to G proteins, which activate the source of
ROS, NADPH oxidase. The activated NADPH oxidase will
produce ROS (e.g., O2
-•), and these, in turn, activate cell
phosphorylation pathways: the mitogen-activated protein
kinases (MAPKs), tyrosine kinases, and phosphoinositol-
3-kinase/Akt kinase (PI3K/Akt). The activated phos-
phorylation pathways activate transcription factors such as
activated protein-1 (AP-1), p53, nuclear factor kappa B
(NFκB), and nuclear E2-related factor 2 (Nrf2), which
stimulate transcription of genes after moving into the
nucleus. Proteins encoded by these target genes in turn
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the phenotypes, such as hypertrophy, inflammation, ne-
crosis and apoptosis of cells and, on the other hand, stimu-
late the production of antioxidants involved in antioxidant
defense [17,20,41] (Figure 2).
Despite the fact that cells of different systems involved
in the regulation of blood pressure perform different
functions, the redox signaling is by and large very similar
and unveil no apparent differences among these types of
cells. NADPH oxidases are primary resources of ROS
in the endothelial cells, vascular smooth muscle cells,
cardiomyocytes, cells of kidneys, as well as cardiovascular
neurons (regions such as the circumventricular organs,
paraventricular nucleus of the hypothalamus, nucleus
tractus solitarii and RVLM) in the brain [10,12,21,42-44].
Ang II is important activator of NADPH oxidases
and stimulator of ROS production in all types of cells
[20,42-46]. Production of ROS is stimulated by shear and
mechanical stress in the vascular smooth muscle cells and
cardiomyocytes, respectively. In addition, MAPKs are re-
sponsible for major effects of ROS such as proliferation,
hypertrophy, and apoptosis in these cells [20,42,45-47].
The same signaling is also proposed to mediate the in-
crease in sympathetic nerve activity, vasopressin release
and drinking behavior induced by Ang II (Table 1).
Mitogen-activated protein kinases
The MAPK family includes serine-threonine protein ki-
nases that play an important role in the transmission of
extracellular signals from cell membrane to the nucleus.
Activation of MAPKs and signal transduction dependsFigure 2 Redox-sensitive intracellular signaling in hypertension.on series of phosphorylating events that allow interaction
of multiple signaling pathways. MAPK phosphorylation
cascades can be negatively regulated by MAP phosphatases
that dephosphorylate/deactivate individual MAPKs [49].
The MAPK pathways are involved in the regulation of cell
proliferation, differentiation, transformation and death, as
well as in vasoconstriction [50]. Three main subgroups of
MAPKs were discovered in the vascular system of mam-
mals: (a) extracellular signal-regulated kinases (ERKs);
(b) c-Jun N-terminal kinases (JNKs); (c) p38-MAPK.
MAPK pathways; all can be activated by many extracellular
and intracellular stimuli such as growth factors (Ang II,
vascular endothelial growth factor, platelet-derived growth
factor) [51], inflammatory cytokines, and cellular stress
[52]. Oxidative stress is a particular type of such stress that
induces activation of MAPK pathways [53]. Studies have
shown that increased production of ROS is responsible
for activation of redox-sensitive p38-MAPK, which might
be involved in the functional and structural changes asso-
ciated with hypertension [54]. In SHR, p38-MAPK is es-
sential for collagen synthesis and mediates the growth of
vascular smooth muscle cells [51]. The major source of
ROS involved in kinase activation is NADPH oxidase. Al-
though the precise mechanisms of redox-sensitive MAPK
activation are not fully understood, the likely mechanisms
include: (a) oxidation of cysteine residues of receptors for
growth factors and cytokines; (b) oxidative modification
of intracellular kinases involved in the MAPK signaling
cascade; (c) deactivation and degradation of MAPK phos-
phatases that maintain the MAPK pathway in the inactive
state [52].
Table 1 Redox-sensitive intracellular signaling in different cells
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Activation of tyrosine kinases by ROS plays an import-
ant role in the remodeling of the cardiovascular system
associated with hypertension. In vascular smooth muscle
cells and other cells, the ROS activate non-receptor tyro-
sine kinases such as Janus kinase 2 (JAK2), proline-rich
tyrosine kinase 2/cell adhesion kinase (PYK2/CAK) and
Src tyrosine kinase, or the receptor tyrosine kinases, such
as the receptor for epidermal growth factor (EGF) [55-57].
Particular attention is paid to the EGF receptor and JAK2
tyrosine kinase in smooth muscle cells. The EGF receptor
is activated by Ang II via ROS. Its activation is necessary
for activation of the ERKs and for the growth of vascular
smooth muscle cells [58]. The JAK2 tyrosine kinase is also
activated by Ang II and ROS and is essential for the induc-
tion of cytokines and thrombin-induced heat-shock pro-
tein in vascular smooth muscle cells and for subsequent
induction of inflammatory response [59].
Akt kinases
The Akt kinase (or protein kinase B) is a serine/threo-
nine kinase that plays an important role in many cellular
processes and its activation in the PI3K/Akt pathway de-
pends on the upstream PI3K. The activated Akt kinase
phosphorylates various downstream effector molecules,
such as glycogen synthase kinase-3, procaspase-9, tran-
scription factors AP-1 and E2F [60], and is thus involved
in modulation of cellular functions. The Akt kinase cas-
cade is implicated in the processes of cell survival andits anti-apoptotic effects are mediated by phosphoryl-
ation of several proteins involved in apoptosis, such as
the pro-apoptotic Bad protein. In addition to its effect
on cell survival, Akt kinase plays an important role in
protein synthesis, in the development of hypertrophy
[61], and its activation was found to play a role in infarct
size limiting mechanisms following cardiac ischemic in-
jury [62]. Dysregulation of Akt leads to diseases of major
unmet medical need such as cancer, diabetes, cardiovas-
cular and neurological diseases [63].
The PI3K/Akt kinase signaling pathway is also in-
volved in the metabolic control and regulation of glucose
transport and glycogen synthesis. The Akt kinase can be
activated by a variety of growth stimuli: the platelet-
derived growth factor, EGF, insulin, thrombin, and the
nerve growth factor (NGF) [64]. It is also known that
the oxidative stress induced by ROS is accompanied by
activation of Akt kinase. Akt kinase activation by ROS
and Ang II has been documented in smooth muscle cells
[61]. In myocardium, Akt kinase has been considered as
a reperfusion injury salvage kinase, counteracting oxida-
tive stress-induced cell damage through a compensatory
protective pathway [65]. In the RVLM of brain stem,
ROS activates PI3K/Akt signaling via oxidation and
phosphorylation of the phosphatase and tensin homolog
deleted on chromosome 10, which is a negative regulator
of PI3K signaling [66]. This redox-sensitive overactivation
of PI3K/Akt signaling contributes to neural mechanisms of
hypertension in SHR. Changes in Akt kinase activation
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sive Wistar rats. Eight weeks after the treatment, the
systolic blood pressure is increased, alongside with an in-
crease in matrix metalloproteinase-2. These changes are
accompanied by activation of Akt kinase, an increase in
ROS accumulation, inhibition of SOD activity, induction
of inducible NOS protein expression and caspase-3 acti-
vation [67]. In human endothelial cells, Akt kinase was
found to phosphorylate the eNOS at serine-1177, and
this is connected with eNOS activation and production
of NO. The activation of eNOS through the Akt kinase
was observed also by shear stress and insulin [60].
RhoA/ROCK pathway
The Rho-associated protein kinase (ROCK) is a serine/
threonine kinase. For its activity, ROCK requires the
binding of the small G-protein RhoA. The RhoA/ROCK
signaling pathway is stimulated by many agonists such
as Ang II, thrombin, ET-1, and NE. Increased activity of
this pathway was observed in atherosclerosis and pul-
monary hypertension, and this signaling has been impli-
cated in many major cardiovascular diseases such as
hypertension, heart failure, and myocardial infarction. A
role of this pathway in the regulation of several cellular
functions such as gene expression, contraction, migration,
and proliferation has been reported [68]. Moreover, it
has been demonstrated that this pathway downregulates
eNOS phosphorylation through inhibition of Akt kinase
[69], and is involved in the modulation of eNOS gene ex-
pression by affecting the stability of its mRNA [70]. In vas-
cular smooth muscle cells, the effects of RhoA/ROCK
pathway on the decreased NO production were associated
with increased vascular contractility. Moreover, inhibitors
of RhoA or ROCK can decrease the systolic blood pres-
sure in hypertensive rats [71]. Essential hypertension
in human is associated with increased Rho/Rho-kinase-
dependent mechanisms and ROCK activity [72].
Redox-sensitive transcription factors and nuclear factors
in hypertension
There are several transcription factors, including AP-1,
p53, NF-κB, Nrf2, whose activity is sensitive to oxidative
stress. AP-1 was first identified as a transcription factor
that binds to the cis-element of the methallothionein hu-
man genes encoding proteins that are involved in cell
proliferation and apoptosis in response to various stimuli,
including the oxidative stress. Redox-sensitive upregulation
of AP-1, c-jun or c-fos have been observed in the RVLM of
the hypertensive animals [73]. In deoxycorticosterone
acetate-induced hypertension, elevated inflammation and
tissue damage in cardiac and vascular muscle cells are at-
tributed to oxidative stress-associated activation of AP-1
[74]. In this animal model of hypertension, dysfunction of
circulating endothelial progenitor cells is related to ETAreceptor-mediated and oxidative stress-associated over-
expression of p53 [75]. In addition, NF-κB activation by
ROS induces the cytosolic and mitochondrial oxidative
stress and tissue injury that contribute to renal dysfunction
observed in SHR [76].
AP-1 binds to the antioxidant response element (ARE)
of target genes, where Fos and Jun proteins may hetero-
dimerize Nrf2 in the presence of electrophiles and oxi-
dants [1]. Activation of gene transcription via the ARE is
mediated primarily through the Nrf2 transcription fac-
tor. Under normal conditions, the activity of Nrf2 is
negatively regulated by protein Kelch-like ECH associ-
ated protein 1 (Keap1) that binds to Nrf2 and keeps it in
the cytoplasm. Exposure to xenobiotics, NO and/or ROS
induce the transcription of Keap1/Nrf2/ARE‐dependent
genes whose functional products protect against a wide
array of subsequent challenges [77]. Free Nrf2 is trans-
located into the nucleus, where it binds ARE enhancer
and activates ARE-dependent transcription of antioxidant
stress genes to trigger the cellular defense response [78,79].
Therefore, redox-sensitive activation of nuclear enhancer
Nrf2 serves as a self-defense feedback mechanism to pre-
vent sustained oxidative damage.
In addition to enzymatic degradation, detoxification of
ROS and electrophiles is also important in protecting
cells from oxidative damage. Genes regulated through
the ARE are involved in the production of antioxidants
that directly inactivate ROS (such as catalase, superoxide
dismutase), detoxify xenobiotics (glutathione-S-transferase,
thioredoxin, NAD(P)H quinone oxidoreductase) and affect
the production of glutathione and phase-II detoxification
enzymes (e.g., γ-glutamate cystein ligase, heme oxygenase-
1). All these genes are highly sensitive to increases in
oxidative stress [80]. Moreover, several redox-sensitive ki-
nases, such as protein kinase C, PI3K/Akt, MAPKs, casein
kinase-2 [81], are involved in the regulation of Nrf2 activ-
ity. These kinases regulate the stability and localization of
Nrf2 by its phosphorylation on serine or threonine residues
in a cell type-specific manner [80].
Emerging evidence indicates that activation of Nrf2/
ARE signaling differs during acute versus chronic stress
conditions. During acute oxidative stress, oxidized mole-
cules modify multiple cysteine residues in Keap1, caus-
ing Nrf2 to be released from connection with Keap1.
Nrf2 is translocated into the nucleus and induces tran-
scription via the ARE genes [78,82]. During a prolonged
oxidative stress, the activity of Nrf2 is turned off by glyco-
gen synthase kinase 3β (GSK3β). The activated GSK3β
phosphorylates the Fyn tyrosine kinase, causing its reloca-
tion to the nucleus [83]. Fyn phosphorylates Nrf2, which
leads to expulsion of Nrf2 from the nucleus, Nrf2 binds to
Keap1 and is degraded in consequence [84]. This mechan-
ism leads to attenuation of antioxidant and detoxificant
response in long term oxidative stress. Only recently the
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cascade gained interest on its role in pathogenesis of
oxidative stress-associated hypertension. The mammalian
Nox4 of the NADPH oxidase possesses antioxidant
activity through Nrf2-dependent upregulation of antioxidant
heme oxygenase-1 (HO-1) [85]. Catalase overexpression
ameliorates maternal diabetes-induced perinatal program-
ming and development of hypertension in adulthood,
mediated, at least in part, by triggering the Nrf2-HO-1
defense system [86]. On the other hand, Nrf2-deficient
mice show reduced pulmonary expression of antioxidant
glutathione, and this renders them highly susceptible to
hyperoxia-induced oxidative lung injury [87].
SOD isoforms and management of hypertension
For the cell to maintain ROS homeostasis there is a deli-
cate balance existing between the production and degrad-
ation of the radicals [88,89]. The later involves activation of
SOD isoforms, which are the first natural antioxidant
defense proteins that improve redox balance. There are
three SOD isoforms, namely the cytosolic copper-zinc
SOD (CuZnSOD, or SOD1), mitochondrial manganese
SOD (MnSOD, or SOD2), and the extracellular SOD
(ecSOD, SOD3). They are the products of different genes,
but catalyze the same reaction for dismutation of O2
-• to
H2O2 [90]. The SOD function as a signaling molecule in
blood vessels and cardiomyocytes have been discussed
[15,91]. Applications of antioxidant gene therapies based
on the SOD genes, HO-1 gene, or glutathione peroxidase
gene in cardiovascular diseases have been presented and
summarized [92]. Application of individual SOD isoform
in the therapy of hypertension has been described [93].
Zimmerman et al. [94] were the first to report in vivo
gene delivery of adenoviral vectors encoding SOD1. They
found that both superoxide production from Ang II
infusion and the induced hypertension were prevented by
overexpression of CuZnSOD. A causal relationship be-
tween biochemical correlates of oxidative stress and
neurological hypertension was established after a gene
transfer by microinjection of adenovirus encoding SOD1,
SOD2 or catalase into the RVLM, which promotes a long-
term reduction of blood pressure in SHR [95]. In consist-
ent to the findings, a gene therapy based on SOD1 gene
transduction by a bacterial gene delivery system results in
blood pressure decrease, regulation of SOD and NOS ac-
tivities, and a protection against oxidative stress [96].
SOD2 is present mainly in the mitochondria of endo-
thelial cells and less in mitochondria of vascular smooth
muscle cells [90]. Mitochondrial oxidative damage is one
of the main pathogenic cellular mechanisms involved in
pathogenesis of hypertension, making the selective tar-
geting of the mitochondria with potent antioxidants a
promising approach in the therapeutic strategy of these
diseases. Overexpression of SOD2 reduces oxidative stressin mitochondria and promotes antihypertensive effects
[90]. Preservation of the mitochondrial electron trans-
port capacity in RVLM with a highly mobile electron
carrier, CoQ10, reduces arterial pressure in SHR and
attenuates the pressor response of normotensive
Wistar-Kyoto rats to Ang II infusion [7,33]. Transgenic
mice with SOD2 overexpression attenuates hyperten-
sion induced by Ang II [97]. This situation is similar to
mice treated with mitochondrial-targeted antioxidant
mitoTEMPO, while non-target antioxidant TEMPOL was
not effective [98]. Reduction in oxidative stress by intra-
venous transduction of cDNA of the SOD1 and SOD2
genes leads to a decrease in blood pressure, reversal of
neuronal NOS gene upregulation in the left ventricle, and
a decreased mitochondrial damage in adult SHR [99].
SOD3 is located in the extracellular space and binds to
the cell membrane through a heparin-binding domain. It
is the second most abundant SOD isoform in blood ves-
sels and is produced mainly by smooth muscle cells.
SOD3 is very important in endothelium-mediated vasodila-
tion because of its location in the interstitium between
endothelial cells and vascular smooth muscle cells. It
enables safe diffusion of NO from endothelial cells into
smooth muscle cells [100]. EcSOD-deficient mice have sig-
nificantly higher degree of hypertrophy, ventricular dilation
and myocardial fibrosis [101]. Studies using overexpression
revealed the protective effects of SOD3 in the blood
vessels. Gene transfer of SOD3-encoding cDNA reduces
superoxide levels in blood vessels and decreases arterial
pressure in SHR [102].
Conclusions
Radical signaling offers several possibilities and strategies
of modulating ROS homeostasis in the management of
hypertension. Individual SOD isoforms can be influenced
using gene transduction and SOD mimetics. Other strat-
egies include inhibition of NADPH oxidase activity, preser-
vation of mitochondrial electron transport chain capacity,
increases in BH4, modulation of the signaling and phos-
phorylation pathways, such as MAPK, Akt kinase, and
RhoA/ROCK signaling pathways. All these possibilities and
strategies have been reported to alleviate ROS accumula-
tion and to protect against oxidative stress to a different
degree in the animal models of hypertension. In addition,
modulation of the redox-sensitive transcription factors, as
well as stimulation of antioxidant response through the
Nrf2-ARE pathway may also prove to be a useful strategy
in future. All these possibilities and strategies should be
further studied in the search for new therapeutical ap-
proaches in management of hypertension.
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